All Access

Health Tech Deals

Health Tech Deals Alerts

Alert

Standard

Health Tech Deals Thought Bubble

Thought Bubble

mustard

BFD Expert Voices - Health Tech Deals

BFD Expert Voices

PhaseV, a clinical trial and development software startup, raised a $50 million Series A, CEO Raviv Pryluk tells Axios exclusively.

Why it matters: Pharma's need for efficient clinical trials has never been more stark amid FDA upheaval.

Pryluk declined to disclose PhaseV's valuation. 

Follow the money: Accel and Insight Partners led, joined by existing investors Viola Ventures, EXOR and LionBird.

PhaseV has ambitious development goals and "will probably raise again in two to three years from now — and that Series B will be substantial," Pryluk says, telling Axios its next funding round could broach three digits.

Boston-based PhaseV has raised $65 million since being founded in 2023.  

How it works: PhaseV is developing AI and machine learning algorithms to accelerate clinical trials and drug development.

Its platform aims to help with clinical trial site selection and trial design, and it is being further developed to support clinical trial recruitment and operations, and causal disease modeling. 

PhaseV has 30 global biotech clients and seven large pharma customers, Pryluk says. 

What they're saying: "We can now support most of the pivotal decisions that pharma companies need to make during clinical development," Pryluk says.

"Whether it's finding the right dose, right indication, right patient population or even the design of the trial as well as dealing with massive amounts of data."

Friction point: Patient recruitment is becoming increasingly difficult, heightening demand for technology solutions to ease that burden. 

"PhaseV is coming up from the other side, saying that if we can be even smarter about how we design the study, we can reduce the number of patients you need by 20% or 30% on day one," Accel partner Matt Robinson says.  

Stunning stat(s): It can take more than 10 years to get a new drug to market — and clinical development has a 90% failure rate on average.

The bottom line: "If there's one thing that we've learned, it's that our clients want a vertical solution, not a point solution," Pryluk says.

"They want us to solve not only their design challenges but execution as well as the analysis."

Exclusive: PhaseV raises $50M Series A to optimize clinical development

Pharma's need for efficient clinical trials has never been more stark amid FDA upheaval.

Illustration of a hand pouring out a test tube full of liquid money.

PhaseV, a clinical trial and development software startup, raised a $50 million Series A, CEO Raviv Pryluk tells Axios exclusively.Why it matters: Pharma&#x27;s need for efficient clinical trials has never been more stark <a class="gtmContentClick" data-vars-link-text="amid FDA upheaval" data-vars-click-url="https://www.axios.com/2025/04/03/drug-industry-worries-fda-delays" data-vars-content-id="ec5120f9-4e60-4008-8831-8b3fb408dd43" data-vars-headline="Exclusive: PhaseV raises $50M Series A to optimize clinical development" data-vars-event-category="story" data-vars-sub-category="story" data-vars-item="in_content_link" href="https://www.axios.com/2025/04/03/drug-industry-worries-fda-delays" target="_self">amid FDA upheaval</a>.

topics

politics-policy

epstein-files

donald-trump

2026-midterm-elections

immigration

behind-the-curtain

race-and-equity

technology

privacy-tech-regulation

automation-and-ai

tiktok-news

big-tech

social-media

cybersecurity

economy

social-security

inflation

tariffs

federal-reserve

jobs

transportation

business

stock-market-news

retail-news

crypto

media

elon-musk

dealmaking

health

rfk-jr

drug-prices

axios-explains-abortion

public-health

world

israel

axios-explains-ukraine

iran

russia

china

energy-climate

nuclear-energy

climate-energy-policy

climate-change

extreme-weather

alternative-energy

electric-vehicles

science

emerging-tech

biomedicine

newsletters

charlotte

boulder

detroit

kansas-city

columbus

austin

dallas

atlanta

washington-dc

nw-arkansas

chicago

indianapolis

nashville

richmond

colorado-springs

houston

san-francisco

seattle

boston

des-moines

salt-lake-city

philadelphia

denver

phoenix

new-orleans

miami

twin-cities

raleigh

san-antonio

portland

san-diego

tampa-bay

cleveland

huntsville

pittsburgh

axios-local

axios-pro

axios-live

the-axios-show

Exclusive: PhaseV raises $50M Series A to optimize clinical development

What to read next